Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial.
|
Clinical Added Value
no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication.
|
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
w06dqCcJ2C4P1Yca